Upstream regulator analysis using Ingenuity Pathway Analysis.

Upstream regulators predicted based on genes that were significantly different for lesional skin before and after treatment with IFX (n = 379). Subset of “significant” transcription factors are shown that had an overlap p-value [26]. Six additional upstream regulators, E2F4, E2F1, PBRM1, NFYB, MYBL2 and NFkB, had low overlap p-values, but there wasn’t sufficient data about known relationships with targets to predict an activation state. Although no upstream regulator was predicted to be activated or inhibited for the IFX-response in CD14+ or CD14− cells, some still had low overlap p-values.Upstream regulator analysis using Ingenuity Pathway Analysis.